Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
6 lessons
11mCeriello et al. followed Italian diabetes clinics for two decades and compared persistent GLP-1 users with those who stopped. The association is striking, but observational data cannot prove causation.
9mUBT251 is a once-weekly GLP-1, GIP and glucagon receptor agonist in development in China. Two phase 2 trials published in Cell Metabolism in October 2026. Here is what they measured, how to read the numbers, and why they can't be ranked against retatrutide.
9mTirzepatide is the dual GIP/GLP-1 receptor agonist behind Mounjaro (type 2 diabetes) and Zepbound (weight management, sleep apnea). Here's what it is, what the trials showed, how it compares with semaglutide and retatrutide, and how to get evaluated by a licensed clinician.
6mMacupatide is the Lilly code name beside eloralintide that most people skip. This beginner guide explains what it is — and what not to invent about dosing yet.
7mEloralintide is only half the Lilly amylin headline. Macupatide shows up in the same ClinicalTrials.gov cluster. Here's the combo literacy guide.
7mEfsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.
Also available at /blog for legacy links.